Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Stephens

Stephens began coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a report released on Monday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $65.00 price target on the stock.

Several other analysts also recently issued reports on the stock. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target for the company in a research report on Monday, August 26th. Truist Financial reiterated a “buy” rating and set a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Wells Fargo & Company upped their target price on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Morgan Stanley lifted their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. Finally, Guggenheim increased their price objective on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $52.13.

Kymera Therapeutics Trading Up 0.1 %

Shares of NASDAQ KYMR opened at $44.11 on Monday. The firm has a market capitalization of $2.86 billion, a P/E ratio of -18.85 and a beta of 2.21. The firm’s 50-day moving average price is $46.99 and its 200-day moving average price is $41.83. Kymera Therapeutics has a 1-year low of $18.89 and a 1-year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. During the same period in the prior year, the business earned ($0.90) EPS. The firm’s revenue for the quarter was down 20.9% on a year-over-year basis. Equities research analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. 15.82% of the stock is owned by insiders.

Institutional Trading of Kymera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Values First Advisors Inc. bought a new stake in shares of Kymera Therapeutics during the third quarter valued at about $61,000. Quarry LP bought a new position in shares of Kymera Therapeutics in the third quarter worth $95,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after buying an additional 504 shares in the last quarter. Comerica Bank boosted its stake in Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares during the period. Finally, Ameritas Investment Partners Inc. grew its position in Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after buying an additional 295 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.